172 related articles for article (PubMed ID: 15809480)
1. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
Kim JH; Czernin J; Allen-Auerbach MS; Halpern BS; Fueger BJ; Hecht JR; Ratib O; Phelps ME; Weber WA
J Nucl Med; 2005 Apr; 46(4):587-95. PubMed ID: 15809480
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
[TBL] [Abstract][Full Text] [Related]
3. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
6. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
7. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
[TBL] [Abstract][Full Text] [Related]
8. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
[TBL] [Abstract][Full Text] [Related]
9. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
[TBL] [Abstract][Full Text] [Related]
10. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
13. PET and PET-CT for evaluation of colorectal carcinoma.
Delbeke D; Martin WH
Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
16. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
18. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
19. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT for staging of penile cancer.
Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
